Drugs / N-Acetylcysteine Amide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05994534 | Oct 2023 → Aug 2026 overdue | cystinosis | Nacuity Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04355689 | Sep 2020 → Jun 2025 | Usher syndrome | Nacuity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07290530 | Dec 2026 → Jul 2029 expected | Usher syndrome, retinitis pigmentosa | Nacuity Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07710196 | Aug 2026 → Feb 2029 expected | Usher syndrome, retinitis pigmentosa | Nacuity Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetylcysteine amide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07290530 ↗ |
| Known as | NPI-001 | “N-acetylcysteine amide (NPI-001) tablets (250 mg), taken BID” NCT07290530 ↗ |
| Route | Oral | “oral tablet” NCT04355689 ↗ |